CSL, an Australian-based biopharma company, plans to invest approximately $1.5 billion over the next five years to expand its presence in the United States, subject to board of directors approval.
“The U.S. is the world’s leading source for plasma, the main component of plasma derived therapies,” Paul McKenzie, CSL CEO and managing director, said. “These important medicines are often the most effective or only therapies available for many rare or serious diseases. By expanding our onshore production capacity in the U.S., we are deepening our commitment to patient care, creating high-quality jobs and driving innovation in the U.S.”
Expansion is part of the company’s commitment to meet the growing clinical need for immunoglobulin. It will strengthen U.S. manufacturing capabilities of plasma-derived therapies, help secure the U.S. medicine supply chain and create hundreds of jobs.
CSL employs more than 29,000 people worldwide, and its products are used in more than 100 countries. It operates three businesses, including King of Prussia-based CSL Behring, and its portfolio includes treatments for hemophilia and immune deficiencies, influenza vaccines and iron deficiency, dialysis and nephrology therapies.
The company has invested more than $3 billion into its U.S. operations since 2018, and American workers represent approximately 65 percent of its work force.